

Amy Hamilton

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3174441/publications.pdf>

Version: 2024-02-01

40
papers

1,458
citations

623734

14
h-index

434195

31
g-index

40
all docs

40
docs citations

40
times ranked

1889
citing authors

#	ARTICLE	IF	CITATIONS
1	Endoscopic Prediction of Crohn's Disease Postoperative Recurrence. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 680-688.	1.9	13
2	Diet and gut microbiome in gastrointestinal disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 237-245.	2.8	25
3	Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 318-331.	8.1	20
4	Non-invasive Serological Monitoring for Crohn's Disease Postoperative Recurrence. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 1797-1807.	1.3	10
5	Efficacy of drug and endoscopic treatment of Crohn's disease strictures: A systematic review. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 344-361.	2.8	11
6	Elucidation of <i>Proteus mirabilis</i> as a Key Bacterium in Crohn's Disease Inflammation. <i>Gastroenterology</i> , 2021, 160, 317-330.e11.	1.3	58
7	Sa513 FOOD AS A RISK FACTOR FOR THE DEVELOPMENT AND PERPETUATION OF CROHN'S DISEASE. AN INTERNATIONAL CASE-CONTROL STUDY OF FOOD AND FOOD ADDITIVE INTAKE FROM BIRTH TILL NOW. THE ENIGMA STUDY.. <i>Gastroenterology</i> , 2021, 160, S-530.	1.3	1
8	Combined Targeted Treatment Using Biologic-Tofacitinib Co-Therapy in Chronic Active Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, e105-e106.	1.9	2
9	Novel strain-level resolution of Crohn's disease mucosa-associated microbiota via an ex vivo combination of microbe culture and metagenomic sequencing. <i>ISME Journal</i> , 2021, 15, 3326-3338.	9.8	11
10	Magnetic resonance enterography for predicting the clinical course of Crohn's disease strictures. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 980-987.	2.8	15
11	Luminal microbiota related to Crohn's disease recurrence after surgery. <i>Gut Microbes</i> , 2020, 11, 1713-1728.	9.8	22
12	Development and Validation of Surveys to Estimate Food Additive Intake. <i>Nutrients</i> , 2020, 12, 812.	4.1	3
13	P849 Urease-positive proteobacteria in Crohn's disease identified by novel ex vivo mucosal microbe culture combined with metagenomic sequencing (MC-MGS): the ENIGMA study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S548-S549.	1.3	1
14	DOP81 Utility of a simple blood test for mucosal healing monitoring is accurate in post-operative Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S078-S079.	1.3	2
15	P195 MRI is predictive of, and anti-TNF treatment changes, the clinical course of Crohn's disease strictures. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S188-S188.	1.3	0
16	P852 Characterisation of Crohn's disease mucosa-associated microbiota by a novel combination of microbe culture and metagenomic sequencing (MC-MGS): the ENIGMA study. <i>Journal of Crohn's and Colitis</i> , 2019, 13, S550-S550.	1.3	0
17	Anti-TNF Therapeutic Drug Monitoring in Postoperative Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 653-661.	1.3	22
18	<i>Proteus</i> spp. as Putative Gastrointestinal Pathogens. <i>Clinical Microbiology Reviews</i> , 2018, 31, .	13.6	111

#	ARTICLE	IF	CITATIONS
19	Visceral adiposity predicts postoperative Crohn's disease recurrence. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1255-1264.	3.7	80
20	Editorial: visceral fat as a predictor of postoperative recurrence of Crohn's disease—Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 1552-1553.	3.7	0
21	Serologic antibodies in relation to outcome in postoperative Crohn's disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1195-1203.	2.8	21
22	Microbial Factors Associated with Postoperative Crohn's Disease Recurrence. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 191-203.	1.3	86
23	Comparison of Fecal Inflammatory Markers in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 1086-1094.	1.9	21
24	Cost-effectiveness of Crohn's disease post-operative care. <i>World Journal of Gastroenterology</i> , 2016, 22, 3860.	3.3	9
25	Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high-risk patients—a POCER study analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 867-879.	3.7	115
26	Effect of Intestinal Resection on Quality of Life in Crohn's Disease. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 452-462.	1.3	30
27	Crohn's disease management after intestinal resection: a randomised trial. <i>Lancet</i> , 2015, 385, 1406-1417.	13.7	475
28	Tu1289 Preventing Crohn's Disease Recurrence After Resection With Adalimumab: Role of Drug and Anti-Drug Antibody Levels. <i>Gastroenterology</i> , 2015, 148, S-849.	1.3	0
29	Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After Surgery. <i>Gastroenterology</i> , 2015, 148, 938-947.e1.	1.3	241
30	S597 Serological Antibodies for the Prediction of Post-Operative Recurrent Crohn's Disease Results From the POCER Study. <i>Gastroenterology</i> , 2015, 148, S-116.	1.3	0
31	S264 What Causes Recurrence of Crohn's Disease After Intestinal Resection? A Prospective Evaluation of Microbiota, Smoking and Anti-TNF Therapy. Results From the POCER Study. <i>Gastroenterology</i> , 2015, 148, S-60.	1.3	1
32	PO086 Intestinal resection in Crohn's disease is associated with significant and durable improvement in health related quality of life although to a lesser extent in women and smokers. Results from the POCER study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S56-S57.	1.3	0
33	OP023 Optimising post-operative Crohn's disease management: Best drug therapy alone versus endoscopic monitoring, disease evolution, and faecal calprotectin monitoring. The POCER study. <i>Journal of Crohn's and Colitis</i> , 2014, 8, S13.	1.3	10
34	S925j Optimising post-operative Crohn's disease management: best drug therapy alone versus colonoscopic monitoring with treatment step-up. The POCER study. <i>Gastroenterology</i> , 2013, 144, S-164.	1.3	17
35	IBD Clinical. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2012, 27, 96-122.	2.8	0
36	P342 Adalimumab prevents post-operative Crohn's disease recurrence and is superior to thiopurines: Early results from the prospective POCER study. <i>Journal of Crohn's and Colitis</i> , 2012, 6, S146.	1.3	5

#	ARTICLE	IF	CITATIONS
37	1161 Adalimumab Prevents Post-Operative Crohn's Disease Recurrence, and is Superior to Thiopurines: Early Results From the POCER Study. <i>Gastroenterology</i> , 2012, 142, S-212.	1.3	13
38	Su2092 Clinical Risk Stratification Predicts Development of Endoscopic Recurrence After Crohn's Disease Surgery: Early Results From the POCER Study. <i>Gastroenterology</i> , 2012, 142, S-568.	1.3	5
39	Prospective Evaluation of Early Post-Operative Crohn's Recurrence in the Presence of Optimal Drug Therapy " Is Endoscopic Evaluation Worthwhile?. <i>Gastroenterology</i> , 2011, 140, S-786.	1.3	0
40	Childhood antibiotics as a risk factor for Crohn's disease: The <sc>ENIGMA</sc> International Cohort Study. <i>JGH Open</i> , 0, , .	1.6	2